The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | B | Blood and blood forming organs | |
| 2 | B06 | Other hematological agents | |
| 3 | B06A | Other hematological agents | |
| 4 | B06AC | Drugs used in hereditary angioedema | |
| 5 | B06AC04 | Conestat alfa |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 3,500 [iU] |
| Active Ingredient | Description | |
|---|---|---|
| Conestat alfa |
Conestat alfa, a recombinant human complement component 1 (C1) esterase inhibitor (rhC1-INH), is an analogue of human C1-INH and is obtained from the milk of rabbits expressing the gene coding for human C1-INH. C1-INH exerts an inhibitory effect on several proteases (target proteases) of the contact and complement systems. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| RUCONEST Powder for solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
